Earnings Preview: St. Jude - Analyst Blog
April 19 2011 - 6:15AM
Zacks
Medical devices giant St.
Jude Medical (STJ) is slated to report its first-quarter
fiscal 2011 results before the opening bell on Wednesday, April 20.
In its fourth-quarter 2010 commentary, the Minnesota-based company
stated that it expects first quarter adjusted earnings per share of
between 77-79 cents. The current Zacks Consensus Estimate for the
quarter is 78 cents, representing an estimated 4.16% annualized
growth.
With respect to earnings surprise,
St. Jude has posted four positive surprises in the preceding four
quarters and we expect this impressive trend to continue in the
first quarter. St. Jude has produced an average positive earnings
surprise 6.44% over the last four quarters, implying that it has
beat the Zacks Consensus Estimate by that measure.
Fourth-Quarter
Flashback
St. Jude posted
better-than-expected fourth quarter fiscal 2010 results with
adjusted earnings of 75 cents beating the Zacks Consensus Estimates
by a penny while exceeding the year-ago earnings of 64 cents.
Profit climbed 8.9% year over year on the back of growth across the
board.
Revenues leaped 12% year over year
to $1,350 million, beating the Zacks Consensus Estimates of $1,323
million. AGA Medical, which St. Jude acquired in November 2010,
contributed $25 million to the top line.
Sales were boosted by strong
momentum at the company’s implantable cardioverter defibrillator
(“ICD”) business with revenues surging 16% to $458 million. St.
Jude’s new Fortify and Unify ICD devices gained notable traction.
However, strong ICD sales were partly masked by a soft pacemaker
business.
St. Jude’s Atrial Fibrillation and
Neuromodulation franchises posted double-digit growth in the
quarter. Cardiovascular revenues, including AGA Medical’s
contributions, surged 20% to $287 million.
Estimate Revisions
Trend
Agreement
Estimates for the first quarter
reflect limited activity over the past week with just 1 out of 25
analysts having lowered his/her forecast while none raising their
estimates. Estimates have been mixed over the past month with 2
analysts having lifted their forecasts accompanied by a couple of
negative revisions, thereby lacking any directional agreement.
On a somewhat similar note,
estimates for fiscal 2011 demonstrate lack of movements over the
past week with just one analyst (out of 31) having lifted
his/her forecast with a solitary downward revision. Estimates have
edged towards the positive side over the last 30 days with 3
analysts having hiked their forecasts accompanied by 2 reverse
movements.
Encouraging prospects in the
company’s core ICD business, supported by new products, inspire
bullishness in some analysts. On the contrary, heightened
competition in the CRM space (ignited by new product launches by
rivals) coupled with ongoing pricing pressure has prompted some
analysts to tread with caution.
Magnitude
The magnitude of revisions for
first quarter has been static over the last 7 and 30 days, a
reflection of the relative lack of directional pressure. A similar
pattern applies to the estimates for fiscal 2011. The current Zacks
Consensus Estimate for fiscal 2011 is $3.28, representing an
estimated year over year growth of 9.05%.
St. Jude in Neutral
Zone
We remain impressed with St.
Jude’s ability to deliver consistent revenue and earnings
growth and believe that its first quarter results to be supported
by new products. Notably, the company’s Fortify and Unify devices
should help it gain share in the ICD space.
St. Jude should expand its position
in CRM (especially ICDs) with a strong pipeline of new ICD devices
(including the quadripolar CRT systems) scheduled for launch in the
U.S. in 2011. The recent approval of the ShockGuard technology,
designed to be used with the Fortify and Unify systems to reduce
inappropriate and unnecessary shocks to patients with ICDs,
represents an incremental positive for the company.
However, St. Jude and its peers
Medtronic (MDT) and Boston
Scientific (BSX) are increasingly in a tug-of-war to grab
market share in the soft CRM market. Competition has intensified
with the launch of the Protecta line of defibrillators by Medtronic
in March 2011. Tough competition between ShockGuard and Protecta
should aggravate price competition.
Outside the core CRM segment, we
expect revenues from St. Jude’s Neuromodulation business to be
driven by the sustained adoption of its deep brain stimulation
(“DBS”) systems and the Eon Mini SCS system. On the Cardiovascular
front, synergies of the AGA Medical acquisition should boost
results in this division.
While we are impressed with St. Jude’s
solid fundamentals, strong product mix, healthy growth
trajectory and operating leverage, we remain wary of
competition-driven pricing pressure and the dilutive impact of
acquisitions and any unfavorable currency exchange fluctuations on
the bottom line. Currently, we are Neutral on the stock, backed by
a short-term Zacks #3 Rank (Hold).
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
Zacks Investment Research
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2024 to Jul 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jul 2023 to Jul 2024